[Federal Register Volume 60, Number 246 (Friday, December 22, 1995)]
[Notices]
[Pages 66553-66554]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-31153]



-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
[Docket No. 95N-0403]


Drug Export; SURGISCREEN 0.8 Percent, Reagent Red Blood 
Cells

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing that 
Ortho Diagnostic Systems, Inc., has filed an application requesting 
approval for the export of the human biological product 
SURGISCREEN 0.8 percent, Reagent Red Blood Cells to 
Australia, Austria, Belgium, Canada, Denmark, The Federal Republic of 
Germany, Finland, France, Iceland, Ireland, Italy, Japan, Luxembourg, 
The Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, 
Switzerland, and The United Kingdom.

ADDRESSES: Relevant information on this application may be directed to 
the Dockets Management Branch (HFA-305), Food and Drug Administration, 
12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857, and to the contact 
person identified below. Any future inquiries concerning the export of 
human biological products under the Drug Export Amendments Act of 1986 
should also be directed to the contact person.

FOR FURTHER INFORMATION CONTACT: Cathy E. Conn, Center for Biologics 
Evaluation and Research (HFM-610), Food and Drug Administration, 1401 
Rockville Pike, Rockville, MD 20852-1448, 301-594-2006.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of 
the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) 
provide that FDA may approve applications for the export of human 
biological products that are not currently approved in the United 
States. Section 802(b)(3)(B) of the act sets forth the requirements 
that must be met in an application for approval. Section 802(b)(3)(C) 
of the act requires that the agency review the application within 30 
days of its filing to determine whether the requirements of section 
802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act 
requires that the agency publish a notice in the Federal Register 
within 10 days of the filing of an application for export to facilitate 
public participation in its 

[[Page 66554]]
review of the application. To meet this requirement, the agency is 
providing notice that Ortho Diagnostic Systems, Inc., 1001 U.S. Highway 
202, Raritan, NJ 08869-0606, has filed an application requesting 
approval for the export of the human biological product 
SURGISCREEN 0.8 percent, Reagent Red Blood Cells to 
Australia, Austria, Belgium, Canada, Denmark, The Federal Republic of 
Germany, Finland, France, Iceland, Ireland, Italy, Japan, Luxembourg, 
The Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, 
Switzerland, and The United Kingdom. The SURGISCREEN 0.8 
percent, Reagent Red Blood Cells, is an in vitro diagnostic test kit 
for the detection of unexpected blood group antibodies in test methods 
requiring a 0.8 percent red cell suspension in a low ionic strength 
diluent. The application was received and filed in the Center for 
Biologics Evaluation and Research on November 24, 1995, which shall be 
considered the filing date for purposes of the act.
    Interested persons may submit relevant information on the 
application to the Dockets Management Branch (address above) in two 
copies (except that individuals may submit single copies) and 
identified with the docket number found in brackets in the heading of 
this document. These submissions may be seen in the Dockets Management 
Branch between 9 a.m. and 4 p.m., Monday through Friday.
    The agency encourages any person who submits relevant information 
on the application to do so by (insert date 10 days after date of 
publication in the Federal Register), and to provide an additional copy 
of the submission directly to the contact person identified above, to 
facilitate consideration of the information during the 30-day review 
period.
    This notice is issued under the Federal Food, Drug, and Cosmetic 
Act (sec. 802 (21 U.S.C. 382)) and under authority delegated to the 
Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the 
Center for Biologics Evaluation and Research (21 CFR 5.44).

    Dated: December 4, 1995.
James C. Simmons,
Director, Office of Compliance, Center for Biologics Evaluation and 
Research.
[FR Doc. 95-31153 Filed 12-21-95; 8:45 am]
BILLING CODE 4160-01-F